Budget impact of Varegacestat
3 evidence topics · 20 sources
Summary: price status and comparator prices
- Immunome reported in its third quarter 2026 Form 10-Q that it has “no drugs approved for commercial sale”. The report quotes no price, commercial dosage form, or launch date for varegacestat. Immunome's topline call presentation states “>90% anticipated payer coverage” and that orphan designation “has favorable pricing implications”.
- Nirogacestat (OGSIVEO) U.S. wholesale acquisition cost: $7,746.58 for each of the 100 mg and 150 mg tablet packages, in a SpringWorks Connecticut price disclosure dated 01/05/2026, which states that the WAC “may not represent actual transactional prices.” The prescribing information describes the package as one blister card with 14 tablets and gives a recommended dosage of 150 mg twice daily.
- Nirogacestat WAC at introduction: $29,000 for a 180-count bottle of 50 mg tablets, dated 12/4/2023 (Vermont Attorney General new drug report).
- England: anticipated list price of £15,189.04 per 56 pack of 150 mg tablets (company submission to NICE), available to the NHS with a discount whose size is commercial in confidence.
- Germany: G-BA annual treatment cost of €260,760.82 per patient after statutory rebates (LAUER-TAXE as last revised 1 February 2026), for the first year of treatment, with a treatment duration of one year (365 days) assumed when the product information specifies no maximum.
Summary: eligible population
- A literature review (Bektas et al. 2023) identified no study of desmoid tumor prevalence; the incidence studies it found were all conducted in European countries. Most U.S. population figures in the report are company estimates.
- SpringWorks Therapeutics (Form 10-K, 2025): 1,000 to 1,650 new patients diagnosed each year in the United States; approximately 5,500 to 7,000 patients actively managed in any given year over the next decade, based on market research with feedback from over 400 physicians; and approximately 11,000 patients receiving physician care annually, from ICD-10 claims between October 2023 and October 2024.
- Immunome (October 2026 corporate presentation): 1,000-1,650 patients diagnosed each year and “10-11,000 actively managed patients in the US”, citing Bektas et al. (2023) and a footnote reading “Immunome Analysis”. The same presentation states that patients may receive “~1.5–2 years of treatment”, citing Immunome primary market research.
- England (NICE TA1199 resource impact): 223 people eligible for nirogacestat in year 1, with uptake of 50%, 60%, and 75% and 112, 117, and 125 people starting treatment in years 1, 2, and 3.
- Germany (G-BA): approximately 350 to 630 patients eligible for nirogacestat, taken from the company dossier and described by the G-BA as subject to uncertainty.
Summary: health technology assessments and sales of nirogacestat
- NICE TA1199 recommends nirogacestat for progressing desmoid tumors that need systemic treatment in adults, only under the company's commercial arrangement. NICE reports that the company concluded an acceptable ICER would be around £35,000 per QALY gained, that the committee judged the estimates based on its preferred assumptions to be within the range considered an acceptable use of NHS resources, and that the exact cost-effectiveness estimates cannot be reported because of confidential discounts. The discount size, the De-Fi utilities mapped to EQ-5D, and the treatment-use estimates from SpringWorks market research are also confidential.
- The G-BA rated the extent of added benefit of nirogacestat as a “Hint for a minor additional benefit”.
- SpringWorks recorded U.S. net product revenue from OGSIVEO of $5.4 million for 2023 (sales began in December 2023) and $172.0 million for 2024.
- Merck KGaA, which acquired SpringWorks on July 1, 2025, reported Ogsiveo net sales of €134 million for 2025, €63 million for the first quarter of 2026, €75 million for the second quarter, and €78 million for the third quarter, when sales increased by 24.5% organically.
- The economic evaluations in the report concern comparators: the NICE model of nirogacestat, a SpringWorks-supported quality-adjusted time without symptoms or toxicity analysis of nirogacestat (Malaviya et al. 2025), and a cost-per-outcome analysis of sorafenib at Medicare Part D rates (Johns et al. 2023). No economic evaluation of varegacestat is quoted.